The outreach comes amid a drop in Indian student enrolments in management programmes at American universities last year, following changes to US student visa policies.
'Any promotional activity carried out under the pretext of disease awareness, influencer engagement, corporate campaigns, or similar activities that create brand recall/product visibility of the prescription shall also be treated as violations.'
For decades, multinational pharmaceutical companies and Indian drugmakers worked in ways that supported each other: MNCs brought innovation and brands, while Indian companies built scale through generics and cost efficiency. There was an important overlap - generic drugs - but this is shrinking fast. And the consequences are reshaping India's gigantic pharmaceutical market.
The government has intensified its Study in India programme and is working closely with universities and states to achieve this goal.
The figures are grim. India accounts for around 19 per cent of global cervical cancer cases and 23 per cent of deaths.
Abbott will exclusively distribute and market Extensior in the country, becoming the second company to secure sole distribution rights for Novo's semaglutide portfolio in India, after Emcure Pharma.
The Centre has allowed companies to begin lab testing immediately after filing applications instead of waiting for detailed scrutiny, in a move to expedite approvals for manufacture, or import of new drugs.
Indian car buyers care more about affordability than technology, keeping ICE vehicles dominant while hybrids emerge as the preferred transition option and EVs struggle in the mass market.
Artificial intelligence (AI) is no longer a side conversation for Indian pharma. It is fast becoming central to how drugs will be discovered, made, and supplied. Along with that shift comes a sharper focus on innovation, on the one hand, and quality and trust, on the other.
Gurugram has overtaken Mumbai to become India's biggest luxury housing market in 2025, recording 24,120 crore in sales of homes priced above 10 crore.
Skoda India is focusing on cleaner fuel options, including CNG and EVs, while compact SUV Kylaq drives volumes, expands first-time buyers and strengthens the brand in India's competitive market
'When young doctors see limited protection, unpredictable careers and an absence of institutional support, they hesitate.'
The tariff removal will lower prices of Harley's large-displacement imported motorcycles, which retail between 14.5 lakh and 45.8 lakh but after the duty cut volumes are expected to remain modest.
Hyderabad is rapidly emerging as a strategic hub for multinational companies (MNCs) deepening their focus on artificial intelligence (AI), life sciences, and global capability centres (GCCs), supported by the city's strong pharmaceutical (pharma) base, deeptech talent pool, and a policy environment that encourages high-value investment.
Jaguar Land Rover will begin assembling premium cars at its new Tamil Nadu plant on February 9, marking a step towards full-scale luxury car manufacturing in India.
India's electric vehicle (EV) markets expanded gains in January compared to the year-ago period, as two-wheeler and passenger vehicle sales triggered a shuffle in the competitive landscape, data from an automobile dealers' association showed.
The India-EU free trade deal could help Indian-made cars enter Europe at lower costs and challenge Chinese dominance.
Maruti Suzuki sold more cars than ever before, earned more money, and saw many first-time buyers choosing small cars again.
The European Union's (EU's) offer to slash tariffs on 97.5 per cent of Indian chemical exports to zero is set to give India's pharmaceutical and medical device firms preferential access to the European markets.
The government's Budget announcements providing tax holiday for data centres, setting up of city economic regions (CERs) and funding to improve infrastructure in Tier-II and -III cities may give an indirect boost to India's realty sector, said industry executives.
© 2026 Rediff.com - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances